144 related articles for article (PubMed ID: 6604099)
1. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
Praz F; Lesavre P
J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
[TBL] [Abstract][Full Text] [Related]
2. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.
McConnell I; Klein G; Lint TF; Lachmann PJ
Eur J Immunol; 1978 Jul; 8(7):453-8. PubMed ID: 211040
[TBL] [Abstract][Full Text] [Related]
3. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
4. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
Mold C; Bradt BM; Nemerow GR; Cooper NR
J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
[TBL] [Abstract][Full Text] [Related]
5. Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
Ramos OF; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
Eur J Immunol; 1987 Jul; 17(7):975-9. PubMed ID: 3111863
[TBL] [Abstract][Full Text] [Related]
6. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
7. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
8. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
9. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
Sármay G; Ramos OF; Klein E; Kai C; Gergely J
Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative complement pathway by normal and transformed cells in homologous and heterologous sera.
McConnell I; Gorman NT; Raniwalla J; Powell P
Eur J Immunol; 1981 Feb; 11(2):126-32. PubMed ID: 6260511
[TBL] [Abstract][Full Text] [Related]
11. Human B lymphocytes activated by Epstein-Barr virus (EBV) or by mitogens suppress mitogen-induced immunoglobulin production.
Tsukuda K; Berczi I; Klein G
J Immunol; 1981 May; 126(5):1810-3. PubMed ID: 6260858
[TBL] [Abstract][Full Text] [Related]
12. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M
J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188
[TBL] [Abstract][Full Text] [Related]
13. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
Servis C; Lambris JD
J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
[TBL] [Abstract][Full Text] [Related]
14. Effect of gangliosides on activation of the alternative pathway of human complement.
Michalek MT; Bremer EG; Mold C
J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
[TBL] [Abstract][Full Text] [Related]
15. Metabolic alterations associated with proliferation of mitogen-activated lymphocytes and of lymphoblastoid cell lines: evaluation of glucose and glutamine metabolism.
Brand K; Leibold W; Luppa P; Schoerner C; Schulz A
Immunobiology; 1986 Oct; 173(1):23-34. PubMed ID: 3492437
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
17. In vitro complement activation by rabbit lymphocytes and thymocytes in autologous serum.
Wilson AB; Lachmann PJ; Coombs RR
Immunology; 1979 May; 37(1):25-34. PubMed ID: 112041
[TBL] [Abstract][Full Text] [Related]
18. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
[TBL] [Abstract][Full Text] [Related]
19. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
[TBL] [Abstract][Full Text] [Related]
20. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
